Advanced Solid Tumor Clinical Trial
Official title:
Implementing Palliative Care: Learning Collaborative vs. Technical Assistance
Verified date | December 2023 |
Source | University of Rochester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies the delivery of the ENABLE palliative care program for patients with advanced cancer. The study compares two methods for delivering ENABLE: Virtual Learning Collaborative (VLC) and Technical Assistance (TA). The focus of the ENABLE palliative care program is on living well, managing stress, patient communication of their personal values and hopes for care, social support, and symptom management. This study may help practices to incorporate ENABLE palliative care services and improve overall mood and quality of life for patients with advanced cancer.
Status | Enrolling by invitation |
Enrollment | 208 |
Est. completion date | September 30, 2025 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | PATIENTS Inclusion Criteria: - Age = 18 - English-speaking - Willing to complete palliative care assessment and ENABLE sessions. - Diagnosed within the last 90 days with an advanced cancer (defined as a newly diagnosed stage III/IV, recurrence, or progressive solid tumor cancer). * Patients can receive any cancer treatment for their advanced cancer while participating in this study. - Expected survival of at least 6 months - Have access to telephone that can receive incoming calls. - Able to provide informed consent. Exclusion Criteria: - Received previous palliative care services (Concurrent palliative care is allowed). PRACTICE SITES Inclusion Criteria: - All participating practice clusters will be asked to identify one (or more) ENABLE Coaches as part of study eligibility to deliver the ENABLE program. - Commitment of the ENABLE Coach(es) to be trained to conduct the palliative care assessment (and ENABLE sessions if the practice plans to implement them). - Desire to implement ENABLE, including presence of an investigator (e.g., Primary Affiliate PI, oncology physician, CCDR Lead) and/or program administrator/supervisor who are willing to be key contacts. - Demonstrated support/buy-in from oncology physicians who are willing to enroll patients. - Agreement of practice leadership and other individuals at the practice cluster to support/participate in the study activities - If necessary, willingness to participate in a phone interview to determine capacity to implement the ENABLE program. ONCOLOGY PHYSICIAN Inclusion Criteria: - Oncology Physician (i.e., medical oncologist or radiation oncologist including trainees) caring for oncology patients. - Oncology physicians must work at a participating practice cluster with no plans to leave that practice site or retire at the time of enrollment into the study. ENABLE COACH Inclusion Criteria: - A registered nurse or advanced practice provider (including a nurse practitioner or physician assistant), a physician (e.g., medical and radiation oncologists, including oncology trainees), or other professionals (e.g., social workers, chaplains) with appropriate credentials and experience to deliver ENABLE. - Individuals with an appropriate clinical license (i.e., a registered nurse, advanced practice provider, or physician, as defined above) may perform the Palliative Care Assessment and any ENABLE sessions and follow-up calls the practice chooses to deliver. - Other professionals (e.g., social workers, chaplains) may deliver ENABLE sessions and monthly follow-up calls for which their credentials and experience are appropriate. - ENABLE Coaches are required to complete appropriate study training for any content delivered. |
Country | Name | City | State |
---|---|---|---|
United States | Michigan Cancer Research Consortium | Ann Arbor | Michigan |
United States | ThedaCare | Appleton | Wisconsin |
United States | Bon Secours Saint Francis Hospital | Charleston | South Carolina |
United States | Columbus NCORP | Columbus | Ohio |
United States | Geisinger Cancer Institute | Danville | Pennsylvania |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Iowa-Wide Oncology Research Coalition | Des Moines | Iowa |
United States | Aspirus Regional Cancer Center | Green Bay | Wisconsin |
United States | Prisma Health System | Greenville | South Carolina |
United States | Hawaii Minority Underserved NCORP | Honolulu | Hawaii |
United States | Hawaii MU NCORP | Honolulu | Hawaii |
United States | Northwell Health/Center for Advanced Medicine | Lake Success | New York |
United States | University of Rochester | Rochester | New York |
United States | Upstate Carolina NCORP | Spartanburg | South Carolina |
United States | Cancer Research for the Ozarks NCORP (CTEP ID: AR012) | Springfield | Missouri |
United States | Cancer Research for the Ozarks NCORP (CTEP ID: IL127) | Springfield | Missouri |
United States | Cancer Research for the Ozarks NCORP (CTEP ID: IL148) | Springfield | Missouri |
United States | Cancer Research for the Ozarks NCORP (CTEP ID: MO043) | Springfield | Missouri |
United States | Cancer Research for the Ozarks NCORP (CTEP ID: MO097) | Springfield | Missouri |
United States | Cancer Research for the Ozarks NCORP(CTEP ID: MO021) | Springfield | Missouri |
United States | MedStar Washington Hospital Center | Washington | District of Columbia |
United States | Roper Hospital | Winston-Salem | North Carolina |
United States | Southeast Clinical Oncology Research Consortium | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of Rochester NCORP Research Base | National Cancer Institute (NCI), University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ENABLE Program Uptake | ENABLE program uptake is defined as the proportion of enrolled patients at participating NCORP practices that complete a Palliative Care Assessment and at least 4 ENABLE sessions. To capture ENABLE program uptake, participating practices will use standardized logs to capture individuals offered the program, enrollment, and completion of the essential ENABLE elements (i.e., palliative care assessment, ENABLE telehealth sessions, follow-up calls). | 65 weeks | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | Survey to measure patient mood. | Baseline, 12 weeks, 24 weeks | |
Secondary | Functional Assessment of Chronic Illness-Palliative Care (FACIT-PAL) | Survey to measure patient quality of life. | Baseline, 12 weeks, 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 |